Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics, Inc. reported a senior leadership change. On June 30, 2026, the company announced an update to its senior management structure and the departure of Cortney Caudill from her role as Senior Vice President and Chief Operating Officer. The company publicly expressed appreciation for Ms. Caudill’s contributions during her tenure.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan reported an exercise-and-sale transaction in company stock. He exercised options to acquire 7,304 shares of common stock at $38.46 per share, then sold 7,304 shares in an open-market transaction at $75.00 per share.
After these transactions, he holds 14,462 common shares directly and 1,500 options to purchase common stock. The filing states the option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026, indicating the timing was set in advance.
HALOZYME THERAPEUTICS, INC. executive Mark Howard Snyder reported routine equity compensation activity involving restricted stock units. On June 12, 5,034 restricted stock units converted into the same number of common shares. The company withheld 2,715 shares at a market price of $69.50 per share to cover tax obligations, which was recorded as a disposition but not an open‑market sale. Following these transactions, Snyder directly owned 49,929 shares of common stock. The filing shows no open‑market buying or selling, only vesting, conversion, and tax withholding mechanics typical of executive compensation.
HALOZYME THERAPEUTICS, INC. executive Darren Snellgrove, who serves as Senior Vice President and Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership. The provided data shows no reported buy, sell, or derivative transactions, indicating this filing is primarily administrative and establishes his insider status.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a series of insider trades in early June 2026. She sold 50,000 shares of common stock in open-market transactions at prices in the mid-to-high $60s per share, according to the Form 4 data.
On the same dates, she exercised 50,000 stock options with an exercise price of $12.07 per share that were due to expire in February 2027. After these transactions, she directly holds 767,780 shares of Halozyme common stock and retains 1,923 options with a $12.07 exercise price expiring in 2027.
The footnotes state that the option exercises and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025, indicating the timing of these trades was set in advance.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported an open-market sale of common stock. On June 1, 2026, she sold 1,625 shares at an average price of $66.21 per share. After this transaction, she holds 43,669 shares of Halozyme common stock directly.
The footnotes state that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to the proposed sale of Common stock of HALO totaling 14,700 shares. The filing lists three vesting entries dated 02/16/2026, 02/20/2026, and 02/23/2026 with quantities 10,879, 2,456, and 1,365 respectively and references 05/15/2026.
HALOZYME THERAPEUTICS, INC. CEO Helen Torley reported a series of option exercises and related share sales in May. Over May 11–13, she exercised options to acquire 50,000 shares of common stock at $12.07 per share and sold 50,000 shares in open-market trades at prices generally in the mid‑$60s to low‑$70s per share. The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025 and that the sales relate to options with a ten-year term expiring in February 2027. Following the reported transactions, she directly holds 767,780 shares of common stock and retains vested options to purchase 51,923 shares.
Halozyme Therapeutics reported multiple Rule 144 sale notices for Common Stock by an affiliated seller. The filing lists sales of 20,000 shares on 03/02/2026, 20,000 on 03/03/2026, 10,000 on 03/04/2026, 20,000 on 04/01/2026, 20,000 on 04/02/2026, and 10,000 on 04/06/2026.
The filing also indicates a planned stock option exercise and sale dated 05/11/2026 involving Common Stock with cash settlement. The seller is identified as Helen Torley at Halozyme Therapeutics.